OncoSec Chief Scientific Officer to Present at Advances in Immuno-Oncology USA Congress
SAN DIEGO and PENNINGTON, N.J., Oct. 8, 2018 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that its Chief Scientific Officer Christopher G. Twitty, PhD, will give a presentation during the Advances In Immuno-Oncology Congress being held in San Diego, October 11-12.
Dr. Twitty's presentation, titled Intratumoral IL-12 in Combination with Pembrolizumab to Treat Metastatic Melanoma in Patients Unlikely to Respond to Anti PD-1 Therapies: Insights Gained from a Biomarker Program, will discuss ongoing research of TAVO (tavokinogene telseplasmid) in combination with KEYTRUDA®(pembrolizumab) as a potential treatment for metastatic melanoma.
The Immuno-Oncology USA Congress will feature over 20 presentations from companies at the forefront of immune-oncology, each presenting insights on new technologies, clinical discoveries and future targets in immuno-oncology research, from cancer vaccines to checkpoint inhibitors, alongside in-depth discussion of patient stratification and clinical development.
"Melanoma is but one of the many types of cancers where the largest part of the immune checkpoint market has yet to be unlocked due to poor/failed/no responses to checkpoint monotherapy, the so-called 'cold tumor' problem, which is well known to this audience," said Dr. Twitty, Chief Scientific Officer of OncoSec. "We are excited to share our finding with them indicating TAVO's ability to recruit more tumor infiltrating lymphocytes (TILs) into the tumors, paving the way for checkpoints to be effective in the largest, but still unresponsive, segment of the checkpoint market."
Details of the presentation are as follows:
Session Title: Translational Immuno-Oncology and Clinical Development
Presentation Title: Intratumoral IL-12 in combination with pembrolizumab to treat metastatic melanoma in patients unlikely to respond to anti PD-1 therapies: Insights gained from a biomarker program
Date and Time: Thursday, October 11, 2018 12:00 PM - 12:30 PM PST
Location: The San Diego Convention Center, Conference Room 5
About OncoSec Immunotherapies
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. OncoSec's lead immunotherapy platform – TAVO (tavokinogene telseplasmid) – enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders. Results from recently completed clinical studies of TAVO have demonstrated a local immune response, and subsequently, a systemic effect as either a monotherapy or combination treatment approach. In addition to TAVO, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its ImmunoPulse® platform. For more information, please visit www.oncosec.com.
Stern Investor Relations
Phone: (212) 362-1200
View original content to download multimedia:http://www.prnewswire.com/news-releases/oncosec-chief-scientific-officer-to-present-at-advances-in-immuno-oncology-usa-congress-300726836.html
SOURCE OncoSec Medical Incorporated
Released October 8, 2018